NCT02248116View on ClinicalTrials.gov

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

September 30, 2000

Conditions
Alzheimer Disease
Interventions
DRUG

Talsaclidine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02248116 - Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type | Biotech Hunter | Biotech Hunter